CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) will host a conference call on March 16, 2023, at 4:30 p.m. ET to discuss its financial results for Q4 and the year ending December 31, 2022. The call will provide a business update regarding the company’s clinical-stage biopharmaceutical developments centered on liver and chronic diseases. CymaBay has received several designations for its treatment, seladelpar, including breakthrough therapy and orphan drug status for primary biliary cholangitis. Interested parties can join the call using the provided numbers or access it via the company's website.

Positive

• Seladelpar has received breakthrough therapy designation by the FDA and orphan drug status in both the U.S. and Europe.

Negative

• None.

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID # 13736281. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and LinkedIn.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

What are the financial results for CymaBay (CBAY) in Q4 2022?

CymaBay will discuss Q4 2022 financial results during the conference call on March 16, 2023.

What is the significance of seladelpar for CymaBay (CBAY)?

Seladelpar is a first-in-class treatment for primary biliary cholangitis, recognized by several regulatory designations.

When will CymaBay (CBAY) provide a business update?

A business update will be provided during the conference call on March 16, 2023.